SpringWorks Therapeutics, Inc. financial data

Location
Stamford, CT
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 09 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 522% % -34%
Quick Ratio 13% %
Debt-to-equity 17% % 3.7%
Return On Assets -44% % 24%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75,322,696 shares 1.7%
Common Stock, Shares, Outstanding 74,986,085 shares 1.2%
Entity Public Float $2,747,091,342 USD 72%
Common Stock, Value, Issued $8,000 USD 14%
Weighted Average Number of Shares Outstanding, Basic 74,885,348 shares 1.5%
Weighted Average Number of Shares Outstanding, Diluted 74,885,348 shares 1.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $49,301,000 USD
Research and Development Expense $196,491,000 USD 15%
Costs and Expenses $129,623,000 USD 13%
Operating Income (Loss) $264,736,000 USD 26%
Nonoperating Income (Expense) $17,431,000 USD -30%
Net Income (Loss) Attributable to Parent $253,933,000 USD 25%
Earnings Per Share, Basic -3 USD/shares 34%
Earnings Per Share, Diluted -3 USD/shares 34%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $63,774,000 USD -46%
Cash, Cash Equivalents, and Short-term Investments $382,700,000 USD -33%
Accounts Receivable, after Allowance for Credit Loss, Current $40,347,000 USD 160%
Inventory, Net $12,417,000 USD 138%
Assets, Current $356,320,000 USD -24%
Property, Plant and Equipment, Net $19,250,000 USD 5.4%
Operating Lease, Right-of-Use Asset $6,578,000 USD 13%
Other Assets, Noncurrent $27,799,000 USD 88%
Assets $505,356,000 USD -23%
Accounts Payable, Current $14,929,000 USD 113%
Employee-related Liabilities, Current $15,596,000 USD -8.9%
Accrued Liabilities, Current $65,639,000 USD 17%
Contract with Customer, Liability, Current $0 USD -100%
Liabilities, Current $82,268,000 USD 19%
Contract with Customer, Liability, Noncurrent $0 USD -100%
Operating Lease, Liability, Noncurrent $5,693,000 USD 2%
Liabilities $87,961,000 USD -1.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax $442,000 USD
Retained Earnings (Accumulated Deficit) $1,236,352,000 USD -26%
Stockholders' Equity Attributable to Parent $417,395,000 USD -26%
Liabilities and Equity $505,356,000 USD -23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $68,759,000 USD 13%
Net Cash Provided by (Used in) Financing Activities $10,609,000 USD -1822%
Net Cash Provided by (Used in) Investing Activities $73,393,000 USD 242%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 75,640,711 shares 1.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,975,000 USD 90%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $64,400,000 USD -46%
Deferred Tax Assets, Valuation Allowance $289,216,000 USD 27%
Deferred Tax Assets, Gross $293,364,000 USD 28%
Operating Lease, Liability $7,912,000 USD 12%
Payments to Acquire Property, Plant, and Equipment $30,000 USD -95%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $253,378,000 USD 25%
Lessee, Operating Lease, Liability, to be Paid $9,065,000 USD 13%
Property, Plant and Equipment, Gross $25,073,000 USD 22%
Operating Lease, Liability, Current $1,700,000 USD 73%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,265,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,254,000 USD 53%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,153,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,175,000 USD 8.6%
Deferred Tax Assets, Operating Loss Carryforwards $147,250,000 USD 22%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,383,000 USD -27%
Additional Paid in Capital $1,678,745,000 USD 7.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $1,101,000 USD 51%
Share-based Payment Arrangement, Expense $108,626,000 USD 6.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%